Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. - Wikidata - wikimedia - TriplyDB

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

http://www.wikidata.org/entity/Q37851006

about

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Interferons: Success in anti-viral immunotherapy.Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.Management of hepatitis C in patients with chronic kidney disease.Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C.Hepatitis C in hemodialysis patients A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α Regulation of cell growth by Notch signaling and its differential requirement in normal vs. tumor-forming stem cells in Drosophila Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea Current and emerging antiviral treatments for hepatitis C infection Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies.Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country Impact of hepatitis C treatment initiation on adherence to concomitant medications.Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.A new era in the treatment of chronic hepatitis C infection.Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.Improving access to treatment for patients with chronic hepatitis C through outreach.Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study.The role of HCV proteins on treatment outcomes.Universal screening for chronic hepatitis C virus.Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options.Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis.Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.Newer therapeutics for hepatitis C

P2860

Q24200189-0B788350-2BE4-4B02-A575-439B05A744C5 Q28074783-2A495C87-898C-4743-BE68-AEE03C9848C4 Q30145658-26C40046-C9C5-4961-BCEF-91199BAB0940 Q31051529-6CF1A0AF-D681-408F-B60C-45AEB2123BDC Q34276038-2DBFC63A-2DC2-4C4E-B5EF-7634337E713A Q34908895-E6A3C1CE-0D6A-401F-AB71-2B710C295B02 Q34932338-D6ECD885-24A3-46A8-8BB7-E47225545D29 Q35152412-BAA5D033-7132-4F1A-9A6A-86BCEAFFE1C3 Q35237329-DD6087CE-B391-4E63-8703-0D3E3A368E78 Q35290680-97B83D7B-1381-44D3-9819-1B4F31A579CF Q35642076-7BC63B6A-021F-46E0-A10A-DBBC7738231B Q36063808-95E68707-E707-465F-832B-434F1F4610F0 Q36073408-E5459149-C6D2-418D-848A-0CCD63CC8673 Q36192804-BE209E86-F587-4962-87C2-7D2A8F5AB3EB Q36391682-3B432593-95D7-4916-9528-C4521F73BEF7 Q36460249-F41DA361-88DD-40A4-8FA9-A159867452ED Q36729900-095331ED-3C6C-4D10-A8AE-B3F38B5B72AB Q36862264-43D72125-444D-4991-A151-56A63A8F9464 Q37187994-244A2D25-6DEF-4815-B5F1-68BA55401139 Q37195548-1D1CD1CE-E8F1-43BD-A118-E89EA6D34EB3 Q37263865-B5134CAA-0289-411D-A01E-6B61888F38F0 Q37279260-534BB1B2-1CDC-412F-B427-CFC4FEB6D10B Q37349005-7734A30D-1227-45E7-B987-849FA4DA6402 Q37424755-F58CED35-2B4F-4237-87DD-7E2298E91BBC Q37626270-F95E73AE-E558-4F3A-AFFD-398F101E0F22 Q38002889-63CB1822-958C-44A3-A1B1-6E03DC4FEF0F Q38051248-033620B1-A489-49E7-9975-00FD28590BFF Q38584280-C402599D-7E8C-4237-9DB9-7A874A0D7EB4 Q38609143-372F0F97-E8CC-4668-AA77-964EE98B93F3 Q38621703-28AB9223-3DC0-4D8A-B208-B80BBE8EEBCD Q38668968-909CE258-355E-4D85-82E1-CC503F8D77E1 Q38685582-46A45D1B-CFA5-4E48-A147-279B24995282 Q38800419-DCAAB745-32E3-41D0-87C6-A1635BEAEED1 Q38832988-AB0E4C9C-E454-4854-8B71-BA48F7E4C460 Q38837174-D23E7A6F-5A31-4D44-983B-8B7D5DAB7D0B Q38903835-09A4F3A6-F26F-4A73-AB02-ED3E5D5BA57D Q39396566-6F13E953-3F0C-4512-91D7-B6D16609772C Q40213917-061F59A4-6642-4A90-BB7F-0FF19BA5BE8C Q40902801-983A3CC8-52BC-4C05-95B9-19D7FF5F2953 Q40903024-D7B3B8DF-F863-48D4-B8EE-81B4D32803A5

P2860

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

http://www.wikidata.org/entity/Q37851006

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

@en

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

@nl

type

label

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

@en

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

@nl

prefLabel

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

@en

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

@nl

P1433

Q37851006-6CBD49FE-0A52-4B73-8671-6AE0F6017EF9

P1476

Q37851006-23C609C1-AD51-4A98-A260-26128BFA3DDE

P2093

Q37851006-07538531-6FBD-44D8-9637-3224D6871A90

Q37851006-105BDCCD-74F8-4948-9624-2FDA56F02A4C

Q37851006-25046EFE-8F73-41F6-BDFD-572F8092ABC8

Q37851006-8562AA9E-8322-4413-ADB0-79042780215E

Q37851006-92B1330D-6B0C-4D0A-A762-B9B935C97280

Q37851006-9D189615-3FED-4C32-9AB0-9B63FFB51028

Q37851006-D1A57C61-77AD-4C24-80AC-3EB33A4D1F73

Q37851006-F74BA03D-B7C0-43B1-B456-579C8DBFE760

P2860

Q37851006-07738E49-A6C3-4EF3-A4D1-5C914E1E0D6F

Q37851006-08D784BB-7248-4ABF-99BC-0D14D1487329

Q37851006-0A2FEEAC-D648-4E13-9C09-CDD555683D30

Q37851006-0D9B83BF-24B6-4C0C-A568-B4A5F364E09E

Q37851006-0F67CA55-F2BF-4BC6-88AF-BB5691E77761

Q37851006-16FAC30E-1167-45D5-8929-8F90F4ED1F1A

Q37851006-1A64B53E-3277-4787-8BF7-D9EC781604D5

Q37851006-1AFC6F93-84BB-4075-9D5D-EE0C4706B679

Q37851006-1B6207D4-3DB2-49CC-8123-83ACAFB482E8

Q37851006-1B9C2D7A-FC1F-4E8D-97CC-147A97F1AF96

P2888

Q37851006-492D5D41-2049-4E61-B3DE-24F30072B57A

P304

Q37851006-F6A4650C-4B39-416A-962E-68F865BA09B2

P31

Q37851006-53C0DB62-2A6E-4E38-B2E4-B593261AAAF9

P356

Q37851006-F9701D79-5092-4660-9B92-A16FDD757BEB

P407

Q37851006-03ACB0BE-3F83-4198-BCA6-44E1D920A2A0

P433

Q37851006-9866CE18-D8B4-4E92-94E5-2DDBAF8D5F11

P478

Q37851006-7A61615E-5A00-41C9-975E-9A43CC051078

P50

Q37851006-3B558D51-297D-4D25-8FBC-2D4A50F26C71

P577

Q37851006-61B69A1F-37C4-4682-A060-14FB8F5CB56E

P5875

Q37851006-0E45C58F-8776-4EF0-A23F-3E3C47926680

P698

Q37851006-E25B9FE4-475D-48B2-B9B7-4490F7D340A1

P356

NRGASTRO.2011.21

P1433

Nature Reviews Gastroenterology & Hepatology

P1476

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

@en

P2093

Bela Hunyady

http://www.w3.org/2001/XMLSchema#string

Cihan Yurdaydin

http://www.w3.org/2001/XMLSchema#string

Curtis Cooper

http://www.w3.org/2001/XMLSchema#string

Jidong Jia

http://www.w3.org/2001/XMLSchema#string

Mark S Sulkowski

http://www.w3.org/2001/XMLSchema#string

Mitchell L Shiffman

http://www.w3.org/2001/XMLSchema#string

Olav Dalgard

http://www.w3.org/2001/XMLSchema#string

Pavel Ogurtsov

http://www.w3.org/2001/XMLSchema#string

P2860

The 5-HT3 receptor as a therapeutic target

The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin.

Interferon Alpha Treatment and Thyroid Dysfunction

Global epidemiology of hepatitis C virus infection

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Side effects of interferon-alpha therapy

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Diagnosis, management, and treatment of hepatitis C: an update

P2888

nrgastro.2011.21

P304

212-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRGASTRO.2011.21

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Markus Peck-Radosavljevic

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50348931

http://www.w3.org/2001/XMLSchema#string

P698

21386812

http://www.w3.org/2001/XMLSchema#string